Therapeutic | Isatuximab |
Target | CD38 |
Heavy Chain | QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS |
Light Chain | DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK |
100% seqID Fv Structure | 4cmh [Fvs: BC] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4cmh [Fvs: BC] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (January '23) | Approved |
Estimated Status (January '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2014 |
INN Year Recommended | 2015 |
Companies Involved | ImmunoGen, Huntsman Cancer Institute, Roche, Sanofi |
Conditions Approved | Multiple myeloma |
Conditions Active | Acute myeloid leukaemia, Precursor cell lymphoblastic leukaemia-lymphoma, Colorectal cancer, Diffuse large B cell lymphoma, Hodgkin's disease, Solid tumours, Urogenital cancer |
Conditions Discontinued | Non-small cell lung cancer, Prostrate cancer, T-cell lymphoma |
Notes |
SAbDab papers
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]
Thera-SAbDab paper
Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]